. Author manuscript; available in PMC: 2012 Sep 1.

Published in final edited form as: Cancers (Basel). 2012 Jun 27;4(3):618–657. doi: 10.3390/cancers4030618

Table 5.

LECP incorporation into tumor-induced lymphatic vessels.

Model	Cell origin or type	Tag	Markers	Time point of analysis	Integration of LECP into LV	Ref.
Rip1Tag2 insulinoma (m)	BM Cells (-T cells)	GFP	Podo, LYVE-1, Prox1	5–7 weeks ^a	3.5% GFP⁺/Prox1⁺ ^b 3.5% GFP⁺/LYVE-1⁺ ^b 3% GFP⁺/Podo⁺ ^b	[23]
TRAMPC-1 prostate cancer (m)	BM cells (-T cells)	GFP	Podo, LYVE-1, Prox1	3–4 weeks ^c	minimal GFP⁺/Prox1⁺ 2.8% GFP⁺/LYVE-1⁺ ^b 4.1% GFP⁺/Podo⁺ ^b	[23]
B16-F1 melanoma (m)	Cultured Podo⁺ BM-MNC	DiI	LYVE-1	7 days ^a	8.5% of LV contained DiI⁺ cells	[53]
T241 fibrosarcoma (m)	CD34⁺/VEGFR-3⁺ BM-LECP	GFP	LYVE-1	1–4 days ^a	detected, not quantified	[15]
T241 fibrosarcoma (m)	CD34⁺/VEGFR-2⁺ BM-LECP	GFP	LYVE-1	1–4 days ^a	detected, not quantified	[15]
Multiple intestinal neoplasia (m)	Hematopoietic stem cells	GFP	LYVE-1	6 weeks ^a	detected, not quantified	[217]
Rip1Tag2 insulinoma (m)	BM Cells (-T cells)	GFP	LYVE-1, F4/80	5–7 weeks ^a	detected, not quantified	[23]
Rip1Tag2 insulinoma (m)	CD11b⁺ cells	GFP	LYVE-1, Prox1	3 weeks ^a	detected, not quantified	[23]
Rip1Tag2 insulinoma (m)	Common myeloid progenitor cells	GFP	Podo, LYVE-1	3 weeks ^a	detected, not quantified	[23]
TRAMPC-1 prostate cancer (m)	Native CD11b⁺ cells	GFP	Podo, LYVE-1, Prox1	3–4 weeks ^c	detected, not quantified	[23]
EL4 lymphoma & Lewis lung carcinoma (m)	Native myeloid cells	β-gal	CD31, Prox1	10–14 days ^c	detected but lacked Prox1, not quantified	[219]

LV, lymphatic vessels; (m), mouse; BM, bone marrow; Podo, podoplanin; BM-MNC, bone marrow mononuclear cells; DiI (1,1'-dioctadecyl-3,3,3'3'-tetramethylindocarbocyanine perchlorate), dye used for cell tracking; (H), human;

time after adoptive transfer of progenitor cells;

percentage of LEC;

time after tumor initiation.